Isaac Cheng

Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards, including NuCana (NASDAQ: NCNA), Advanced Cell Diagnostics (sold to Bio-Techne), Liquidia Technologies, and Meissa Vaccines, Amylyx Pharmaceuticals, Cognoa, Artugen Therapeutics, Cognito Therapeutics, Atea Pharmaceuticals, Big Health, and Tallac Therapeutics.

Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company that was sold to Allergan. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine.